1. Ecosystem for Single Cell Analysis
Single cell biology is reshaping our understanding of cellular function. It is now clear that understanding biology at the single cell level will be critical to answering previously irresolvable questions in the areas like cancer research, stem cell biology, immunology, developmental biology and neurobiology. Smpl Bio research interest for single cell analysis (SCA) is driven not only by the rapidly expanding market opportunity represented by SCA, but also by the deep knowledge and passion for the field brought by several co-founders including Dr. Craig Nelson.
While transformative, SCA has created a host of ancillary needs in the research community. One of the most glaring of these is the need for single cell biologists to easily and reliably estimate the number of cells they will need to analyze, choose between NGS and targeted experiments, choose the appropriate number and most informative genes to measure in a targeted design, and process the huge amounts of data that arise from having more samples than ever before. While making every cell a sample has revolutionized opportunities, it has also exponentially multiplied experimental design and interpretation challenges.
Smpl Bio is designing a complete bioinformatics ecosystem for single cell analysis. These solutions will empower end users with novel analytics that makes their research productive, efficient and easy by offering a proprietary, powerful, end-to-end bioinformatics solution.
Most “omics” research (genomics, proteomics, metabolomics or transcriptomics) have been transformed by new technologies and are intensely data centric, longitudinal, and quantitative. Data sets are enormous, diverse and complex, and require sophisticated analytics for processing. However, most existing software solutions have limitations: they are generally retrospective (focusing on data analysis but neglecting to enable experimental design), often labor intensive, restricted to use by professional bioinformaticians, and incapable of providing end-to-end solutions that can take a scientist from discovery, through validation, development and delivery. The ability of Smpl Bio’s platform to embed into the experimental environment and offer powerful informatics and quality control at every step of the process greatly simplifies experimental workflow and ensures the reliability of the data. Researchers are emboldened to perform primary, secondary and tertiary analyses at the push of a button.
Smpl Bio’s platform is versatile, can accommodate any data type, and is platform agnostic. These features will allow Smpl Bio to address one of the most important requirements of future healthcare research: collaborative multi-omics longitudinal clinical studies. Smpl Bio will allow researchers to easily identify, rapidly test and rigorously validate the biomarkers essential to these studies.
3. Biopharmaceuticals: Translational Research and Companion Diagnostics
Much of the bioinformatics requirements in Pharmaceuticals are concentrated around their biomarker strategies. Almost all disease specific programs have biomarker strategies around their discovery, development, verification and validation processes. Smpl Bio enables a the biological scientist to easily design, analyze and interpret experimental data sets from ‘omics’ related research to generate maximally informative and robust biomarker panels. Given the incredibly high cost of iterative research within big Pharma, the ability to ensure that appropriate hypothesis is being easily framed and tested, and that all data is being analyzed and interpreted rapidly and efficiently has tremendous value.
Smpl Bio envisions to offer customized versions of its bioinformatics platform to enable ‘plug and play’ solutions for the biopharma researchers, so as to integrate within their workflow work and deployed in accordance with their guidelines.
4. Personalized Medicine and Diagnostics
Delivering the right medicine at the right time to the appropriate individual is at the heart of personalized medicine, and commercially available tests based on genomic markers are changing medical practice. Informative and robust biomarkers are absolutely critical to personalized medicine. The quest, to not only develop new personalized medical tests, but also to continuously improve the predictability of existing tests, is often based on discovering and refining unique panels of biomarkers. The successful validation of a unique panel is followed by the development of a multivariate clinical test. Both processes require a robust, evolved and simple bioinformatics solution that can be implemented across research and diagnostics environments; Smpl Bio meets these requirements.
Smpl Bio’s informatics platform will be similarly attractive to other sectors, notably plant genomics. Our objective is to provide customized solutions for production genomics and plant breeding applications.